Daxor Corporation (DXR) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $9.38. It has a SharesGrow Score of 89/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of DXR = $39.98 (+326.2% from the current price, the stock appears undervalued). Analyst consensus target is DXR = $23 (+145.2% upside).
Valuation: DXR trades at a trailing Price-to-Earnings (P/E) of 5.2 (S&P 500 average ~25).
Financials: revenue is $503,424, +343.4%/yr average growth. Net income is $9M, growing at +535.4%/yr. Net profit margin is 1821.5% (strong). Gross margin is 37.5% (-45.3 pp trend).
Balance sheet: total debt is $112,000 against $46M equity (Debt-to-Equity (D/E) ratio 0, conservative). Debt-to-assets is 0.2%. Total assets: $46M.
Analyst outlook: 3 / 3 analysts rate DXR as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 21/100 (Fail), Future 100/100 (Pass), Income 100/100 (Pass).
